Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 18/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3608765 | 0.98 | LMNA (0.41) | LMNACYP2C9TSHRAPEX1SMN1; SMN2 | |
| SCHEMBL3597440 | 0.78 | IP6K1 (0.39) | LMNASMN1; SMN2IP6K1 | |
| Hydrochloric Acid SCHEMBL3613636 | 0.77 | IP6K1 (0.38) | LMNASMN1; SMN2IP6K1 | |
| SCHEMBL3604648 | 0.76 | KCNH2 (0.42) | SMN1; SMN2IP6K1 | |
| Hydrochloric Acid SCHEMBL3599938 | 0.75 | KCNH2 (0.41) | SMN1; SMN2IP6K1 | |
| SCHEMBL1471426 | 0.74 | MMP13 (0.43) | — | |
| Hydrochloric Acid SCHEMBL1471477 | 0.73 | MMP13 (0.42) | — | |
| Hydrochloric Acid SCHEMBL5266451 | 0.72 | LMNA (0.45) | LMNACYP2C9TSHRAPEX1SMN1; SMN2 | |
| SCHEMBL3593054 | 0.72 | KMT2A (0.40) | LMNATSHRSMN1; SMN2 | |
| SCHEMBL1470890 | 0.71 | LMNA (0.43) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232659-A1 | Novel Alkyl Substituted Piperidine Derivatives as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | US | claimed |
| EP-1761518-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123715-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20100056567-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | PETERS DAN | 2010-03-04 | — | — | US | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20070232659-A1 | Novel Alkyl Substituted Piperidine Derivatives as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | US | disclosed |
| EP-1761518-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| WO-2005123715-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | LMNA 4612/4885CYP2C9 488/4885TSHR 433/4885 |
| US-20100056567-A1 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | LMNA 4255/4885CYP2C9 1224/4885TSHR 916/4885 |
| US-20070232659-A1 | Novel Alkyl Substituted Piperidine Derivatives as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | LMNA 4255/4885CYP2C9 1224/4885TSHR 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.